The government must prioritise remaining a member of the European Medicines Agency in Brexit negotiations, after a key Parliamentary vote where it fought off moves to keep it tied to the cu
Valsartan, a drug widely used to control blood pressure is being recalled in several countries around the world because of its chemical ingredient possibly linking to cancer.
Europe’s drugs regulator has issued a temporary staffing contract worth up to £32 million, in order to ensure it has enough hands on deck while it relocates from London as part of Brexit.